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ondary aim of this analysis is to promote an approach to develop more reliable disease 
simulation models in cardiovascular disease. Methods: Data describing LDL-C and 
nfMI+CV Death outcomes were abstracted from several landmark secondary preven-
tion statin trials in clinically stable patient populations (4S, CARE, LIPID, HPS, TNT, 
IDEAL, GREACE, AVERT, and LIPS). Linear (L), quadratic (Q), one-knot linear spline 
(S1L) and two-knot quadratic spline (S2Q) models were fit. RMSE, leave-one-out cross 
validated (LOOCV) and Monte Carlo cross validated (MCCV) RMSE (90% training, 1,000 
replicates) were used to evaluate predictive performance. Predicted event rates based 
on LDL-C = 50mg/dL were estimated to illustrate the clinical implications of each 
model. To encourage full reproducibility and transparency, all raw data and code (R) 
will be made freely available for download online via authors Git repository. Results: 
A total of eight models were fit and evaluated, including four distinct functional 
forms (L, Q, S1L, and S2Q) across two sets of data (all data (A) and data censured for 
high leverage studies(C)). Of all the models evaluated, S2Q-C exhibited the lowest 
RMSE (0.317) while L-C produced both the lowest LOOCVRMSE (0.463) and MCCVRMSE 
(0.389). Model selection had an impact on predicted percentage of events/yr at 50mg/
dL (range= 0.769 to 2.09). ConClusions: This analysis suggests that a linear model 
may be among the most appropriate when describing the relationship between LDL 
and nfMI+CV Death in secondary prevention; however, other models (linear spline 
and quadratic) warrant further investigation. These findings along with additional 
research will help inform more reliable and accurate models of long-term outcomes 
and economic benefit of LDL-C lowering treatment modalities.
PRM66
The woRld healTh oRganizaTion and univeRsal diagnosTic TesTing 
foR susPecTed MalaRia in childRen: is The new Policy cosT-effecTive 
and affoRdable foR sub-sahaRan afRica?
Phillips V.
Emory University, Atlanta, GA, USA
objeCtives: Malaria imposes a substantial global disease burden with 198 million 
cases reported worldwide in 2013. It disproportionately affects sub-Saharan Africa, 
particularly young children and accounts for 14% of the region’s childhood deaths. 
In an effort to improve disease management, the World Health Organization (WHO) 
in 2010 recommended countries test children (age < 5) who present with suspected 
malaria fever and confirm diagnosis rather than treat them presumptively with 
antimalarial drugs, the standard of care to date. While all 47 African countries 
designated as malaria-endemic, have adopted the policy, significant barriers to 
implementation exist. These include costs, uncertainty about the overall health 
benefits, shortfalls in testing supplies and physician practice patterns. Methods: 
We use a decision-analytic approach to assess the policy’s cost effectiveness in three 
countries in sub-Saharan Africa: Angola, Tanzania and Uganda, each representing 
different prevalence/income combinations. Our model includes country-specific 
epidemiologic, cost and behavioral data, including that of physician and caregiver. 
Our primary data sources are national Malaria Indicator Surveys and information 
from each country’s National Malaria Control Program. We use a Markov specifi-
cation to account for multiple fever episodes and estimate the incremental cost-
effectiveness of the testing policy through two-stage micro-simulation models. 
These models capture key dimensions of uncertainty associated with our projec-
tions. Results: We find that diagnostic testing for malaria is cost-saving in Angola. 
In Tanzania the cost per life-year gained is $5.54 and $94.58 in Uganda. Both are cost-
effective compared to the WHO standard of $150 per life-year gained. Our results 
are robust under varying cost, prevalence and behavioral assumptions. Probabilistic 
sensitivity analyses indicate that testing is cost-saving or cost-effective: 80% of the 
time in Angola, 89% in Tanzania, and 69% in Uganda. ConClusions: Our findings 
strongly suggest pursuit of policies that facilitate full implementation of testing, 
including promoting clinician adherence to test results.
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whole-disease Model aPPRoach: MeThodologies and challenges in 
coMMunicaTing The econoMic buRden of RaRe diseases
Shah A., Proach J.
Market Access Solutions LLC, Raritan, NJ, USA
objeCtives: The concept of whole-disease model has rarely been applied in prac-
tice or considered in the published literature. No studies to date have addressed the 
applicability of this approach in rare diseases. This research aims to demonstrate 
the applicability, technique, and framework of the model designed to educate US 
Payers of the estimated patient-level costs and resource utilization, using a rare 
disease as a case study. Methods: The lack of specific ICD-9-CM code, prevalence 
overestimation, poorly documented US epidemiology data, complex diagnostics, 
and off-label pharmacotherapy were evident in rare diseases. In order to estimate 
patient-level resource utilization, diagnosis costs, and 12-month treatment cost 
from the US Payer’s perspective, a clinical guideline-based approach was developed. 
We reviewed diagnosis and treatment guideline recommendations to develop a 
resource utilization algorithm which was subsequently validated by clinicians to 
reflect the real-world clinical practice. Model cost inputs were derived from pub-
lished resources including the most recent year Medicare Fee Schedules and H-CUP 
National Inpatient Sample database. Adverse event costs associated with the treat-
ments were not accounted for in the model. Results: An interactive, MS-Excel 
based economic model was constructed based on guideline recommendations. The 
model inputs were customizable, allowing flexibility in plan/Payer specific disease 
burden estimation. Cost of diagnosis, pharmacotherapy, and surgical therapies were 
calculated for a single patient over a 12-month period. ConClusions: The study 
demonstrates that the whole-disease model approach can be applied to rare dis-
eases to provide the disease burden estimation, serving as an information tool for 
Payers, for diseases with small patient volume and unknown cost burden. The model 
also provides a platform for manufacturers to: 1) incorporate real-world data as they 
become available; 2) add/remove interventions as the market evolves and; 3) add 
various economic elements to further calculate budget impact or cost-effectiveness 
of an intervention over a product life-cycle.
unvaccinated with the seasonal influenza vaccine and persons vaccinated during 
seasons where vaccine was considered (by the CDC-reported vaccine effective-
ness percentage (VE%= (1-relative risk)*100%)) a suboptimal match for seasonal 
flu strain. Results: Published vaccine effectiveness for a suboptimal seasonal 
influenza vaccination ranged from 39%-63% from flu seasons 2006-2007 through 
2013-2014. This was approximately the same protection observed in the large claims 
database for the same year ranges. When modeled together with cost it was shown 
that this mismatch of vaccination to circulating virus still equated to a substantial 
reduction in burden of disease when vaccinated. Validation of results still ongo-
ing. ConClusions: The burden of disease of influenza significantly decreases 
even when the seasonal influenza vaccine is a suboptimal match to the prevalent 
circulating strain. It is recommended that all persons able to receive the influenza 
vaccination do so, whether or not the match is optimal. It has been demonstrated 
that a suboptimal match effectively decreases the burden of the disease.
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feasibiliTy and accePTabiliTy of MiniMal Modeling value of 
infoRMaTion analyses foR Real-TiMe PRioRiTizaTion decisions wiThin 
a laRge canceR clinical TRials cooPeRaTive gRouP
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objeCtives: Value of Information (VOI) analyses can help align research investments 
with areas that could have the greatest impact on patient outcomes, but many ques-
tions remain concerning its feasibility and acceptability to inform real-world prior-
itization decisions. Our objective was to develop a process for calculating VOI in “real 
time” to inform trial funding decisions within SWOG, a large cancer clinical trials 
group. Methods: We adapted a novel and efficient modeling approach - minimal 
modeling VOI - using a sample of nine phase II/III trial proposals from the Breast, 
Gastrointestinal, and Genitourinary committees reviewed by SWOG’s leadership 
between 2008-2013. We created decision models for each trial proposal and devised 
an efficient process to characterize prior uncertainty in treatment effect by linking 
evidence-based assumptions in a trial’s sample size calculations with the historical 
success rates of SWOG trials. Expected clinical and economic VOI was calculated using 
Bayesian updating methods. We customized the process using iterative stakeholder 
input. Results: The VOI modeling process was feasible and sufficiently captured key 
expected differences in comprehensive outcomes and attendant uncertainty for 8 of 9 
trial proposals. Model construction and calculations took one researcher < 1 week per 
proposal. We accommodated stakeholder input by: a) deconstructing VOI metrics into 
expected health benefits and incremental healthcare costs, b) assuming treatment 
decisions were based on health benefits alone, and c) providing both individual and 
population level results. Following this customization, SWOG generally accepted the 
VOI framework and results for the retrospective analyses and felt that VOI analyses 
would likely be useful in informing future trial proposal evaluations. ConClusions: 
We developed an efficient and customized process for calculating the expected VOI 
of cancer clinical trials that is feasible for use in real-time decision-making and is 
acceptable to stakeholders. Prospective use and assessment of this approach is cur-
rently underway within SWOG.
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alTeRnaTive MeThods foR geneRaTing aRbiTRaRy MaRginal 
disTRibuTions and The iMPlicaTions foR siMulaTion ouTcoMes
Zhuo J.X.
Merck, North Wales, PA, USA
objeCtives: Generating multivariate random variables is essential in disease 
simulation applications. In this study we examine the implications of alternative 
approaches to generate marginal distributions and correlation matrix on simula-
tion outcomes. Methods: We adopt three alternative methods including Cholesky 
Decomposition (CD), CD with conditional matching, and the NORmal-To-Anything 
(NORTA) method to generate a hypothetical simulation sample with arbitrary mar-
ginal distributions and correlation matrix. As the comparator, we also create an 
independent and identically distributed (iid) simulation sample. The samples are 
individually populated in a previously developed type 2 diabetes microsimulation 
model to predict the major clinical endpoints over 15 years. The endpoints include 
all-cause mortality, diabetes-related mortality, and major cardiovascular events. We 
examine the goodness of fit by total deviance, i.e., the aggregated values of the rela-
tive difference between the individual predictions with the endpoints observed in the 
actual data, in the overall and stratified samples. Results: The results show that, 
the model predications deviate from the observed data with an iid sample. Over 15 
years, the model over-predicts all the numbers of endpoint events by 20%, with the 
total deviance of 0.73, and the over-prediction is particularly more pronounced in the 
younger patients. With a sample of a constructed multivariate normal distribution 
using the CD and CD plus conditional matching approach, the deviance is reduced 
to 0.41 and 0.58 respectively. A further improvement is observed when using the 
NORTA method, with the deviance of the endpoints between model prediction and 
actual data further reduced to 0.11. The reduction was mainly contributed by better 
approximations in the dispersion of the risk factors among patients. ConClusions: 
Random sequences generation has important ramification for simulation outcomes. 
Poorly-defined multivariate distributions may significantly distort the simulation 
performance. Given its flexibility for both continuous and discrete variables, NORTA 
method appears to be a preferable approach.
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an evaluaTion of coMPeTing Models foR PRedicTing cv evenT RaTes 
fRoM ldl-c levels in secondaRy PRevenTion
Conner C.
Health Strategy, LLC, Remdond, WA, USA
objeCtives: This study aims to evaluate four alternative models that each describe 
the relationship between LDL-C and CV event rates in secondary prevention. A sec-
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quent untargeted TKI. EGFR testing+gefitinib was a dominant economic strategy 
when compared to commonly used treatment alternatives. Assuming the most con-
servative comparator strategies, EGFR+gefitinib remained cost-effective. Decreasing 
the specificity of EGFR testing (false positive rate) or including a mortality benefit to 
TKI worsened the ICER. ConClusions: Simultaneous reimbursement of the EGFR 
test and gefitinib for first-line treatment of EGFR M+ aNSCLC was a cost-effective 
alternative to no testing and chemotherapy.
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PRogRession of vision loss in PaTienTs wiTh geogRaPhic aTRoPhy- a 
disease Model
Arjunji R.1, Wang F.1, Gutierrez B.1, Bhattacharyya A.1, Alfonso R.1, Williams R.1, Dabbous O.2
1GSK, King of Prussia, PA, USA, 2GlaxoSmithKline, King of Prussia, PA, USA
objeCtives: Geographic Atrophy (GA) affects eight million people worldwide, lim-
its visual acuity (VA) resulting in blindness. Our aim was to forecast the long term 
impact of GA on visual loss and blindness, and the expected benefits of early treat-
ment. Methods: The model was developed using Excel Visual Basic Application 
(VBA) with the following inputs: 1) population characteristics (gender, age at GA diag-
nosis, baseline VA, one eye versus two eyes involvement), 2) health states by VA (no 
visual impairment, visual impairment, blindness and death), 3) rate of VA decline. 
Data of natural progression of GA from Age-Related Eye Disease Study (AREDS) was 
used as the main input for this model. The key outputs of the model under no inter-
vention/hypothetical intervention are: 1) time to loss of functional vision (VA> 20/40), 
visual impairment (VA< 20/80), and blindness (VA≤ 20/200), and 2) time to event curves 
for visual disability and blindness. Results: In a simulated cohort of 500 patients 
diagnosed with GA (with a mean age of 70 years and VA= 20/60), the model estimated 
that 60% of them would develop blindness in the affected eye over their lifetime 
without intervention. On average, they experience four years with visual impairment 
and eight years with blindness. The model also showed that GA patients with younger 
age and worse VA at diagnosis, and faster rate of VA decline are at increased risk of 
attaining blindness. A hypothetical intervention with 25% and 50% efficacy avoided 
1 and 3 years of blindness, respectively. Sensitivity analysis showed that treatment 
efficacy when compared to starting age, starting VA, and rate of VA loss, had the 
highest impact in reducing time spent in blindness. ConClusions: The simulation 
model based on natural history of GA progression showed that effective treatment 
started early at diagnosis can reduce the burden of vision loss among GA patients.
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Review of MeThodological aPPRoaches To geneRaTe PRoPensiTy 
scoRes in MulTilevel daTa
Sarangpur S.1, Jamotte A.2, Thokagevistk K.1, Sherman S.1
1Creativ-Ceutical, Chicago, IL, USA, 2Creativ-Ceutical, Paris, IL, USA
objeCtives: Propensity score matching (PSM) techniques are frequently used in 
analyses of retrospective or observational data. Several approaches have been devel-
oped to account for the hierarchical structure of data in PSM analyses. The aim of this 
study is to identify and review existing multi-level PSM methodologies. Methods: 
Medline and PubMed databases were used to perform a targeted literature review 
to identify studies that use PSM methodologies in multi-level data. The following 
search terms were used: ‘Propensity score’, ‘Multi-level data’, ‘Hierarchical model’ 
and ‘Propensity score matching’. Methodologies that specifically considered the 
challenges of performing PSM with hierarchical data were included in the final 
review. Results: Six strategies were identified in the literature to perform PSM in 
multi-level data. These included 1) Complete pooling (CP); 2) Partial pooling (PP); 3) 
No pooling (NP); 4) Simple single-level modeling (SSLM); 5) “Two stage” modeling 
(TSM); and 6) “Dummy” modeling (DM). CP ignores potential clustering in the data 
and is the most commonly used approach. SSLM differs from CP in that it matches 
patients only within a given cluster. In contrast, the NP method generates separate 
propensity scores (PS) for each cluster and matches prior to pooling. The PP method 
uses random intercept models to generate PS and patients are matched across all 
clusters. The TSM approach first estimates random errors separately and applies 
them in a subsequent PS model that account for clustering, after which patients are 
matched as in the PP method. The DM method simply includes the cluster identifier 
as a fixed effect in the PS model. ConClusions: Performance of each approach is 
dependent on the number of clusters and the sample size in each cluster. A thorough 
investigation of data should be undertaken before selecting an approach to use PSM 
in studies with multi-level data.
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conTRasTing The RelaTive Risk ReducTion of caRdiovasculaR evenTs 
in The coRe diabeTes Model associaTed wiTh single Risk facToR 
changes acRoss alTeRnaTive Risk engines: ukPds68, ukPds82 and 
swedish naTional diabeTes RegisTRy equaTions
Foos V.1, Lamotte M.2, McEwan P.3
1IMS Health, Basel, Switzerland, 2IMS Health Consulting, Brussels, Belgium, 3Health Economics 
and Outcomes Research Ltd, Monmouth, UK
objeCtives: The degree to which predefined risk factor (RF) changes alter life time 
benefits and costs in projections with the IMS-CORE-Diabetes-Model (CDM) has 
been previously reported. The objective of this study was to contrast the relative 
risk reduction of cardiovascular events by individual RF changes using alternative 
risk equations (RE), specifically: UKPDS-68 (UK68-RE), UKPDS-82 (UK82-RE) and the 
Swedish-National-Diabetes-Registry (SNDR-RE). Methods: The CDM was applied 
to estimate annual probabilities for 1st myocardial infarction (MI), 1st stroke, 
ischemic heart disease (IHD) and heart failure (HF) for an intermediate risk type 
2 diabetes individual (age 55 years, HbA1c 8%, SBP 140 mm-Hg, BMI 30 Kg/m2, TC 
250 mg/dl, HDL 50 mg/dl and LDL 170 mg/dl). The relative risk (RR) in association 
with unit RF changes was determined for HbA1c (-1%), body-mass-index (BMI) (-1 
Kg/m2), systolic-blood-pressure (SBP) (-10 mmHg), total-cholesterol (TC) (-10 mg/
dl), (high-density-lipoprotein (HDL) (+5 mg/dl) and low-density-lipoprotein (LDL) 
(-10 mg/dl). Results: The RR of CV endpoints associated with risk factor changes 
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calibRaTing an inTegRaTed PhaRMacoeconoMic-PhaRMacoMeTRic 
Model of coPd TReaTMenT: whaT a diffeRence The vaRiance Makes
Slejko J.F.1, Willke R.J.2
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Pfizer, Inc., New York, NY, USA
objeCtives: The objective was to calibrate a pharmacometric-pharmacoeconomic 
microsimulation model of COPD to ensure that variation resulting from model esti-
mates was consistent with the underlying trial data, thereby providing more accurate 
estimates of the probability of the clinical and economic “success” of drug develop-
ment options based on this model. Methods: A Markov microsimulation model was 
developed to estimate monthly changes in key COPD severity metrics (FEV1 and exac-
erbations) in order to compare a hypothetical FEV1-increasing drug to placebo. The 
pharmacometric model, based on a model-based meta-analysis of COPD trials, was 
used to predict the exacerbation rate (ER) in a group of actual trial patients, given their 
known baseline FEV1.The hypothetical drug increased FEV1 and thereby decreased 
the ER in the treatment group. Costs and utilities were derived from the literature and 
applied to monthly model outcomes. The variance in exacerbations generated by this 
model was calibrated to the variance in the trials underlying the pharmacometric 
model. Model results were compared to those generated by a Markov model without 
such calibration. A common random numbers assumption for non-COPD mortality 
was tested for its effect on variation in health economic outcomes. Results: In the 
reference case, relative to the uncalibrated model, the calibrated model resulted in 
similar outcome means but 15-17 times larger standard deviations (SDs) for exacer-
bations, 6-7 times larger SDs for 1-year costs, and three times larger SDs for QALYs. 
This led to more elliptical ICER scatterplots and flatter cost-effectiveness acceptability 
curves in the calibrated model. Use of common random numbers did not make a sig-
nificant difference in these results. ConClusions: Integration of pharmacometric 
and pharmacoeconomic models provides a basis for outcomes variance calibration 
with actual data. Without calibration, variation induced within a typical Markov 
model may substantially misrepresent true clinical variation and lead to inaccurate 
probabilities of success versus clinical and economic thresholds.
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infoRMing unceRTain Model PaRaMeTeRs ThRough Model calibRaTion: 
huMan PaPilloMaviRus (hPv) Model case sTudy
Minayev P.1, Dasbach E.J.2, Pillsbury M.2
1MSD IT Global Innovation Network @ Prague, Prague, Czech Republic, 2Merck & Co. Inc., North 
Wales, PA, USA
objeCtives: Numerous HPV models have been developed to evaluate the cost-
effectiveness of HPV vaccination. However, uncertainty remains in some key model 
parameters such as the risk of transmission and partner formation and dissolution 
rates. We attempted to identify those parameters that influenced most calibration 
fits for an HPV type 6/11 agent-based model. Methods: We developed an agent-
based HPV model of HPV 6/11 infections and disease (warts) to explore the effect 
of partnership formation and natural history parameters on how well the model 
output fit observed data on HPV 6/11 infections and disease. Our heuristic model 
describes the population in terms of the three groups by individuals’ sexual activity 
level. The activity level is positively correlated with the risk of infection transmission 
or acquisition. Persons belonging to the low and medium risk groups tend to have 
long lasting relationships with low probability of forming concurrent partnerships, 
whereas those in the highest risk (most active) group tend to engage in short and 
often concurrent partnerships. Results: We found that the most sexually active 
group of people is responsible for forming a power-law tail in the partnership statis-
tics reported in surveys and has the biggest impact on the infection spread, and that 
durations of short-term partnerships, along with risk group and age mixing patterns, 
have the biggest impact on the model fit. In combination, these factors also determine 
the characteristic shapes of the warts age-specific incidence curves with the peak 
occurring in the female population approximately five years earlier than in the male 
population. ConClusions: The transmission dynamics of HPV 6/11 infection and 
disease depend greatly on the short-living partnership networks. Accounting for the 
formation of such partnerships is critical to achieving acceptable model fits. Further 
research is necessary to explore how accounting for partnership formation affects 
cost-effectiveness analyses of HPV vaccination strategies.
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PRacTical issues in develoPing econoMic Models foR TaRgeTed 
TReaTMenTs
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objeCtives: A reimbursement process for targeted therapies was introduced in 
2011 requiring joint economic assessment of both the new treatment and associ-
ated diagnostic test. Thus the emphasis of the evaluation was no longer simply 
on the effectiveness of the new treatment in targeted patients but also in patients 
inappropriately treated due to false positive test results. A submission for subsidy 
of EGFR mutation testing to determine eligibility for first-line gefitinib treatment of 
patients with advanced NSCLC was undertaken. Methods: An individual patient 
simulation was used to model current SOC for NSCLC, no test and first-line plati-
num-based doublet chemotherapy versus the proposed intervention, EGFR mutation 
test and gefitinib treatment for EGFR M+ patients and SOC for EGFR M- and EGFR 
unknown patients. The IPASS Study (NCT00322452) confirmed the benefit of TKIs in 
EGFR M+ patients, but also the potential harm to EGFR M- patients in the first-line 
setting. Data were thus available for EGFR M+ and EGFR M- patients treated with 
both gefitinib and SOC. This information was critical to development of a screening 
module and survival curves. Results: EGFR testing regimens to target TKI treat-
ment at various points in the patient’s life from diagnosis through to palliative care 
were compared. The results were most sensitive to choice of comparator such as: 
inclusion of switch maintenance following doublet chemotherapy; proportion of 
patients receiving second-line therapies including targeted TKI; and use of subse-
